Breaking News

CureVac Receives Approval to Initiate Clinical Trial of SARS-CoV-2 Vaccine Candidate

First subjects will be vaccinated In Belgium and Germany.

By: Contract Pharma

Contract Pharma Staff

The Belgian Federal Agency for Medicines and Health Products (FAMHP) has approved the Phase 1 clinical trial for CureVac’s vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium. First subjects will be vaccinated at the Institute for Tropical Medicine in Tübingen and the Ghent University Hospital (Belgium), the Tropical Institute of the University Hospital Munich, LMU (Germany), and the Hannover Medical School (Germany).   CureVac´s mRNA vaccine candi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters